Tango Therapeutics, Inc. TNGX
21.79 USD +0.91 (+4.38%)
Nov 6, 2026, 11:44 AM EST
20.91 Day range 21.88
7.37 52-week range 34.39
- YTD
- +145.88%
- 1 year
- +171.97%
- Market cap
- 3.68B
- Revenue (ttm)
- 53.81M
- Profit margin
- -229.92%
- EPS (ttm)
- -0.85
- Shares out
- 168.61M
- Forward P/E
- -13.75
- YTD return
- +145.88%
- 1-year return
- +171.97%
- Volume
- 295.53K
- Avg volume
- 3.35M
- Open
- 20.91
- Previous close
- 20.87
- Day's range
- 20.91 – 21.88
- 52-week range
- 7.37 – 34.39
- Beta
- 1.22
- Analysts
- Strong Buy
- Price target
- 47.09 (+116.2%)
- Earnings date
- Nov 10, 2026
1M -0.07 (-0.32%)
Key statistics
- Enterprise value
- 2.92B
- PEG ratio
- 0.00
- Price / sales
- 72.63
- Price / book
- 3.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -71.87M
- Total cash
- 1.01B
- Total debt
- 31.99M
- Return on equity
- -21.34%
- Short % of float
- 26.86%
- 50-day average
- 23.54
- 200-day average
- 22.43
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 47.09 +116.2% upside
Now 21.79
- Target (low)
- 24.00
- Target (mean)
- 47.09
- Target (high)
- 69.00
Ratings (0m) 13 12 buy · 1 hold · 0 sell
- Strong buy1
- Buy11
- Hold1
- Sell0
- Strong sell0
Next earnings
Nov 10, 2026
Expected Nov 10, 2026. Consensus EPS estimate -0.35083.
Financials — quick view
TNGX Revenue — quarterly 0
TNGX Net income — quarterly -55.34M
TNGX EPS — quarterly -0.37
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 10, 2026 | Sep 30, 2026 | -0.35297 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.31722 | -0.37 | -0.05 | -16.64% |
| May 13, 2026 | Mar 31, 2026 | -0.3137 | -0.32 | -0.01 | -2.01% |
| Mar 5, 2026 | Dec 31, 2025 | -0.31 | -0.29 | +0.02 | +6.45% |
| Nov 4, 2025 | Sep 30, 2025 | 0.01 | 0.13 | +0.12 | +1,200.00% |
| Aug 5, 2025 | Jun 30, 2025 | -0.35 | -0.35 | 0.00 | 0.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 29, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2026 | William Blair | init | — | Outperform |
| Aug 18, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 12, 2026 | Guggenheim | main | Buy | Buy |
| Jul 17, 2026 | Mizuho | main | Outperform | Outperform |
| Jul 15, 2026 | JP Morgan | init | — | Overweight |
About Tango Therapeutics, Inc.
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to reverse the immune evasion effect of serine-threonine kinase (STK) 11 loss-of-function mutations to treat lung cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tangotx.com
News
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 
Tango Therapeutics to Participate in Guggenheim's 3rd Annual Healthcare Innovation Conference 
Tango: Upgrading 'Buy' Based On ESMO 2026 Vopimetostat PDAC Data And Pathway Advancement Clarity 
HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target 
Crude Oil Surges 4%; SLB Shares Jump Following Upbeat Q3 Earnings 
10 Health Care Stocks Whale Activity In Today’s Session 
Why Is Tango Therapeutics Stock Trading Lower After Cancer Drug Data? 
12 Health Care Stocks Moving In Friday's Pre-Market Session 
Tango Therapeutics Announces Results From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Daraxonrasib In Patients With Metastatic Pancreatic Ductal Adenocarcinoma And Non-Small Cell Lung Cancer; Study Demonstrated 82% Objective Response Rate, Median PFS Not Yet Reached, And 9M PFS Rate Of 88%, In 22 Patients 
Winnebago Industries Posts Upbeat Q4 Earnings, Joins SpaceX, Super Micro Computer And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on TNGX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARRY DOUGLAS | General Counsel | Sale | Feb 4, 2025 | 66,014 |
| BECKMAN DANIELLA | Chief Financial Officer | Sale | Feb 2, 2026 | 184,297 |
| BOXER CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 5, 2024 | 0 |
| BOXER CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 5, 2024 | 0 |
| CRYSTAL ADAM S | Officer | Sale | Sep 30, 2026 | 115,743 |
| ECOR1 CAPITAL, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | Sale | Nov 6, 2024 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 8.24% | 13,900,620 | 322.22M | Jun 29, 2026 |
| Blackrock Inc. | 7.38% | 12,438,444 | 288.32M | Jun 29, 2026 |
| FMR, LLC | 7.31% | 12,333,339 | 285.89M | Jun 29, 2026 |
| Farallon Capital Management LLC | 7.28% | 12,277,000 | 284.58M | Jun 29, 2026 |
| Boxer Capital Management, LLC | 6.45% | 10,876,219 | 252.11M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 5.92% | 9,980,620 | 231.35M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.61% | 4,395,732 | 101.89M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.41% | 4,065,305 | 94.23M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.16% | 3,649,644 | 84.60M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 1.67% | 2,809,158 | 65.12M | Aug 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.48% | 2,500,062 | 57.95M | Aug 30, 2026 |
| T. Rowe Price New Horizons Fund, Inc. | 0.92% | 1,546,027 | 35.84M | Jun 29, 2026 |